HU 211

Discontinued Product

2861 has been discontinued.

View all NMDA Receptors products.
Description: NMDA receptor antagonist; also NF-κB inhibitor
Alternative Names: Dexanabinol
Chemical Name: (6aS,10aS)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol
Purity: ≥97% (HPLC)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for HU 211

HU 211 is a NMDA antagonist (IC50 = 11 μM for inhibition of [3H]MK-801 binding to rat forebrain membranes). Protects against NMDA- and quisqualate-induced neurotoxicity (EC50 = 3.8 μM) and enhances dopamine D1 receptor activity. Inhibits NF-κB, reducing TNF-α, IL-6 and nitric oxide production, and acts as a free radical scavenger. Exhibits beneficial effects in experimental models of multiple sclerosis, bacterial meningitis, septic shock, epilepsy, and traumatic and ischemic brain injury. Brain penetrant.

Technical Data for HU 211

M. Wt 386.57
Formula C25H38O3
Storage Store at -20°C
Purity ≥97% (HPLC)
CAS Number 112924-45-5
PubChem ID 107778
InChI Key SSQJFGMEZBFMNV-PMACEKPBSA-N
Smiles CCCCCCC(C)(C)C1=CC(O)=C([C@]2([H])[C@](C(C)(C)O3)([H])CC=C(CO)C2)C3=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for HU 211

References are publications that support the biological activity of the product.

Eshhar et al (1993) HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport 5 237 PMID: 8298080

Striem et al (1997) Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the DArgic system. Eur.J.Pharmacol. 338 205 PMID: 9424014

Gallily et al (1997) Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J.Pharmacol.Exp.Ther. 283 918 PMID: 9353414

Juttler et al (2004) The cannabinoid dexanabinol is an inhibitor of the nuclear factor kappa B (NF-κB). Neuropharmacology 47 580 PMID: 15380375

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: HU 211, HU 211 supplier, NF-κB, NF-kappaB, NF-kB, inhibitors, inhibits, decreases, TNF-α, TNF-alpha, IL-6, NO, production, NMDA, antagonists, receptors, Nuclear, Factor, Kappa, B, Cytokine, Signaling, Signalling, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, HU211, Dexanabinol, NF-kB/IkB, 2861, Tocris Bioscience

Citations for HU 211

Citations are publications that use Tocris products.

Currently there are no citations for HU 211.

Reviews for HU 211

There are currently no reviews for this product. Be the first to review HU 211 and earn rewards!

Have you used HU 211?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.